Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Extracellular Vesicles (EVs) & Nanoparticles 2024: Diagnostics, Delivery, Therapeutics

Mei He's Biography

Mei He, Associate Professor, University of Florida

Dr. He is an associate professor from the Department of Pharmaceutics, College of Pharmacy at the University of Florida. She obtained her PhD degree from the University of Alberta and postdoc training from the University of California, Berkeley. Dr. He is the Editorial Board member of Pharmaceutics and AAPS Scientific Programming Committee Track Leader, as well as the Advisory Board Member of journal Lab on Chip (LOC). Her journal review efforts have been recognized as the Outstanding Reviewers in 2018, 2020, and 2021 from the LOC Royal Society of Chemistry. Dr. He Received NIH Maximizing Investigator’s Research Award for Early Stage Investigators in 2019, and she also received the LOC Emerging Investigator Award in 2019. Her multiple publications received the Most Download Articles of 2016 (LOC), the Featured Cover Story of 2018 (LOC), Technology Readers Choice Award of 2018 (SLAS), and Top 100 Read Articles of 2019 (Scientific Reports from Nature Publishing Group). Her recent publication is appeared in the journal of Nature Biomedical Engineering and highlighted as the Editorial Story. Dr. He research brings in novel technology platforms for differentiating, isolating, and intravesicular loading exosomes precisely, which presents a new way for developing precision medicine Dr. He’s innovation leads to 17 pending and issued patents and have been licensed by multiple companies and commercialized on the market. Particularly, she founded a few startup companies for advancing the innovative exosome research.

Mei He Image

Extracellular Vesicle-Based Gene Therapy

Wednesday, 3 April 2024 at 08:30

Add to Calendar ▼2024-04-03 08:30:002024-04-03 09:30:00Europe/LondonExtracellular Vesicle-Based Gene TherapyExtracellular Vesicles (EVs) and Nanoparticles 2024: Diagnostics, Delivery, Therapeutics in Miami, FloridaMiami,

Genome editing is an emerging and powerful therapeutic tool for treating diverse diseases. However, clinical translation has been challenging, due to tremendous limitations in current delivery vehicles such as traditional viral vectors for carrying CRISPR Cas9 systems. Alternatively, extracellular vesicles (EV) based gene delivery is emerging as a safe and highly biocompatible approach for addressing current challenges in gene therapy. We developed a novel Microfluidic Droplet-based EV Electroporation System (µDES), which can handle various cargos loaded into EVs in large throughput and high efficiency. We achieved 10-fold enhancement of loading efficiency and more than 1000-fold increase in processing throughput on loading CRISPR RNP complexes into EVs compared with conventional bulk electroporation. In the Shaker-1 mouse model of dominant progressive hearing loss, we demonstrated the effective delivery of RNP-EVs into inner ear hair cells, with a clear reduction of Myo7ash1 mRNA expression compared to RNP-loaded lipid-like nanoparticles (RNP-LNPs), leading to significant hearing recovery for future clincial translation.

Add to Calendar ▼2024-04-03 00:00:002024-04-04 00:00:00Europe/LondonExtracellular Vesicles (EVs) and Nanoparticles 2024: Diagnostics, Delivery, TherapeuticsExtracellular Vesicles (EVs) and Nanoparticles 2024: Diagnostics, Delivery, Therapeutics in Miami, FloridaMiami,